Vaqta


Also found in: Acronyms.

Vaqta

A vaccine against HAV made of killed hepatitis A virus to stimulate the body's immune system to produce antibodies against HAV. See Hepatitis A.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

VAQTA

(văk′tă)
Hepatitis A vaccine, inactivated.
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
This study, set in Kazakhstan, randomized 4524 patients who had been exposed to hepatitis within the past 14 days to receive either hepatitis A vaccine (VAQTA, Merck) or immune globulin (0.02 mL/kg).
Two vaccines now are approved for use in children 1 year and older, Havrix (GlaxoSmithKline) and Vaqta (Merck).
Later this year, the CDCs Advisory Committee on Immunization Practices is expected to discuss broadening these recommendations for the two currently-licensed hepatitis A vaccines, GlaxoSmithKline's Havrix and Merck's VAQTA. Both are inactivated vaccines, given in two doses at least 6 months apart to children aged 24 months and above.
6-year follow-up of children and adolescents who participated in an efficacy trial of VAQTA (hepatitis A vaccine, inactivated, Merck).
TABLE Recommended dosages and schedules of hepatitis A vaccines Vaccine Age group Dose Volume # Doses Havrix 2-18 years 720 ELU 0.5 mL 2 19 years and older 1440 ELU 1.0 mL 2 Vaqta 2-18 years 25 U 0.5 mL 2 19 years and older 50 U 1.0 mL 2 Vaccine Age group Schedule Havrix 2-18 years 0, 6-12 mos 19 years and older 0, 6-12 mos Vaqta 2-18 years 0, 6-18 mos 19 years and older 0, 6-12 mos ELU, enzyme-linked immunosorbent assay (ELISA) units; U=units FIGURE 1 Hepatitis A by race/ethnicity Rate per 100,000 population Total 10.3 Asian 4.6 Black * 5.5 White * 6.4 Hispanic 20.7 Amer.
Previously, the pediatric/ adolescent formulation of VAQTA was approved for use in persons aged 2-18 years.
The formulation, dosage, and schedule for VAQTA have not changed.
VAQTA is now indicated for active immunization of persons aged [greater than or equal to] 12 months to protect against disease caused by hepatitis A virus.
(92.) Werzberger A, Mensch B, Taddeo C, et al., 6-year follow-up of children and adolescents who participated in an efficacy trial of VAQTA (hepatitis A vaccine, inactivated.
If the Vaqta vaccine is used, two 50-unit doses should be administered on a schedule of 0 and 6 months.
If the Vaqta vaccine is used, 2 50-unit doses should be administered on a schedule of 0 and 6 months.